Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc HMTXF


Primary Symbol: V.HEM

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Closes $403,539 of the Unit Private Placement

Newsfile June 28, 2023

Hemostemix's Private Placement Use of Proceeds

Newsfile June 21, 2023

Hemostemix Announces Unit Private Placement

Newsfile June 1, 2023

TSX Venture Exchange Stock Maintenance Bulletins

Canada NewsWire May 3, 2023

IIROC Trading Resumption - HEM

Canada NewsWire May 2, 2023

Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company

Newsfile May 2, 2023

IIROC Trading Halt - HEM

Canada NewsWire May 2, 2023

Hemostemix' Second Round Interviews with Executive Vice President Business Development Candidates

Newsfile April 3, 2023

Hemostemix Engages Montreal's RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally

Newsfile March 29, 2023

Hemostemix Closes $762,400 of The Unit Private Placement

Newsfile March 21, 2023

Hemostemix Unit Offering Repriced

Newsfile March 8, 2023

Hemostemix (TSXV:HEM) offering US$17.5M in convertible debentures for therapy program

Caroline Egan  March 7, 2023

Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval

Newsfile March 7, 2023

Hemostemix Announces Unit Private Placement

Newsfile February 1, 2023

The Force Family Office Engaged by Hemostemix

Newsfile January 31, 2023

Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland

Newsfile January 30, 2023

Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office

Newsfile January 26, 2023

Hemostemix Wins Arbitration Decision

Newsfile January 24, 2023

Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs

Newsfile January 23, 2023

IIROC Trading Resumption - HEM

Canada NewsWire January 19, 2023